Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study

作者全名："Zheng, Wei; Cao, Xiaoxia; Luo, Jing; Liu, Zhuoting; Que, Wenjun; Guo, Xia; Fan, Rui; Long, Quanxin; Xiao, Fei"

作者地址："[Zheng, Wei; Luo, Jing; Liu, Zhuoting; Que, Wenjun; Guo, Xia; Fan, Rui; Xiao, Fei] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing Key Lab Neurol, Chongqing, Peoples R China; [Cao, Xiaoxia; Long, Quanxin] Chongqing Med Univ, Minist Educ, Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China; [Que, Wenjun] Chongqing Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Chongqing, Peoples R China; [Guo, Xia] Zunyi Med Univ, Affiliated Hosp 2, Dept Neurol, Zunyi, Peoples R China"

通信作者："Xiao, F (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing Key Lab Neurol, Chongqing, Peoples R China.; Long, QX (通讯作者)，Chongqing Med Univ, Minist Educ, Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China."

来源：NEUROLOGICAL SCIENCES

ESI学科分类：NEUROSCIENCE & BEHAVIOR

WOS号：WOS:001101707900003

JCR分区：Q2

影响因子：2.7

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：Inactivated vaccine; SARS-CoV-2; Myasthenia Gravis; Acetylcholine receptor antibody (AchR-Ab); Cohort study

摘要："Background and objectivesMyasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction. No cohort study has investigated the efficacy of inactivated vaccines in patients with MG.Materials and methodsThis prospective observational cohort study included healthy controls (HCs) and patients with MG with or without immunosuppressive treatment. Vaccination occurred between May and December 2021. Patients with MG were subjected to a clinical scale assessment for disease severity. The neutralization antibodies (Nabs) levels were measured in all participants using the pseudovirus neutralization assay.ResultsTwenty-one patients (Female/Male:10/11); age median [interquartile range (IQR)]: 43 [30, 56]) were included in this study. Two patients (2/21) were lost during follow-up after enrollment. No sustained vaccine-related adverse effects occurred in any visit of patients with MG. No exacerbation of MG was observed. Acetylcholine receptor antibody (AChR-Ab) levels showed no statistically significant changes between the first and second visit (median [IQR]: 2.22 [0.99, 2.63] nmol/L vs. 1.54 [1.07, 2.40] nmol/L, p = 0.424). However, levels of AChR-Ab decreased at the third visit (median [IQR]: 2.22 [0.96, 2.70] nmol/L vs. 1.69 [0.70, 1.85] nmol/L, p = 0.011). No statistically significant difference in Nabs levels was found between HCs and patients with MG (median [IQR]: 102.89 [33.13, 293.86] vs. 79.29 [37.50, 141.93], p = 0.147).DiscussionThe safety of the SARS-CoV-2 inactivated vaccine was reconfirmed in this study. No significant difference in Nabs level was found between patients with MG and HCs. Nabs levels correlated with AChR-Ab levels before vaccination and Delta AChR-Ab levels."

基金机构："The authors wish to thank the patients, healthy controls, and the team of research assistants in the First Affiliated Hospital of Chongqing Medical University"

基金资助正文："The authors wish to thank the patients, healthy controls, and the team of research assistants in the First Affiliated Hospital of Chongqing Medical University"